Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 12

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
Accumulated other comprehensive loss(415,719)(428,809)Accumulated deficit(179,667,937)(175,289,630)Total stockholders' deficit(9,563,701)(6,012,089)Total liabilities and stockholders' deficit$18,618,941 $22,101,131 

See accompanying notes.

1

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Three months ended March 31,20252024RevenueRoyalty revenue$25,427 $9,302 Total revenue25,427 9,302 Operating expensesGeneral and administrative2,309,164 2,670,581 Research and development2,297,381 3,353,520 Royalty expense— 7,674 Total operating expenses4,606,545 6,031,775 Loss from operations(4,581,118)(6,022,473)Other income (expense)202,811 (732,883)Net loss$(4,378,307)$(6,755,356)Foreign currency translation adjustments13,090 (39,227)Comprehensive loss$(4,365,217)$(6,794,583)Loss per common share - basic and diluted$(0.50)$(0.81)Weighted average number of shares outstanding:Basic and diluted8,759,053 8,376,189 

See accompanying notes.

2

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Deficit

(Unaudited)

Three Months Ended March 31, 2025AdditionalAccumulatedotherTotalCommon stockpaid-incomprehensiveAccumulatedstockholders'SharesAmountcapitallossdeficitdeficitBalance at Balance at December 31, 20248,700,386 $870 $169,705,480 $(428,809)$(175,289,630)$(6,012,089)Stock-based compensation— — 377,357 — — 377,357 Issuance of common stock, net of issuance costs150,000 15 436,233 — — 436,248 Net loss— — — — (4,378,307)(4,378,307)Foreign currency translation adjustments— —